Docusign: Analysts Anticipate $437.8 Million In Q1 Revenues

Docusign (NASDAQ: DOCU) will be reporting their first quarter 2022 financial results today after market close. Analysts have a consensus $273.06 12-month price target on the company, via a total of 19 analysts, with nine analysts having strong buy ratings, eight analysts having buy ratings, and two have hold ratings. The street high comes in at a $300 price target from Oppenheimer, and the lowest target sits at $210 from Wells Fargo.

13 analysts have revenue estimates for the first quarter. The mean revenue estimate between all 13 analysts is $437.81 million; this number has been revised upwards from $421.12 million at the start of the year. The highest revenue estimate is $454.1 million, while the lowest is $432.83 million.

The analyst consensus for net income for the first quarter is $56.12 million, this is up from the start of the year, when it sat at $41.14 million. The highest net income estimate is $60.90 million, while the lowest is $36.50 million.

Onto EBITDA estimates, there are currently only 7 analysts who have first quarter EBITDA estimates. The mean is currently $73.81 million, with this number having been revised higher from $51.94 million at the start of the year. The street high estimate currently sits at $77 million in EBITDA and the lowest is $65.59 million.

Analysts estimate that quarterly earnings per share will come in at ($0.20), with this number being higher from the ($0.30) estimate at the start of the year. The street high is ($0.03) and the lowest estimate is ($0.32) per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Gold Story Starts With Cash Flow | Gordon Robb – ESGold

Silverco Cusi Mine PEA: Bigger Isn’t Always Better

Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley – Cardiol Therapeutics

Recommended

Total Metals Secures High Grade Critical Minerals Property In Northwestern Ontario

Discovery at Luis Hill Prompts Acceleration of Phase 2 Program for Questcorp

Related News

Trulieve: Canaccord Raises Price Target From $45 To $51

Last week, Trulieve Cannabis (CSE: TRUL) announced that they are acquiring two Pennsylvania companies, PurePen...

Tuesday, September 22, 2020, 02:45:00 PM

Canopy Growth Sees Canaccord Lower Target To $10 After Poor Q3 Results

On February 7th, Canopy Growth Corp (TSX: WEED) reported its fiscal third quarter financial results....

Sunday, February 13, 2022, 01:03:00 PM

Raymond James: 7% Mortgage Rates Are The Breaking Point

It looks as if Raymond James is the first investment bank to throw in the...

Tuesday, October 25, 2022, 03:56:00 PM

Canopy Growth: Consensus Estimates For Q4 2021

Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) announced that they will be reporting their fiscal...

Monday, May 31, 2021, 04:44:00 PM

Cresco Labs: Canaccord, Eight Capital Raise Price Targets

Cresco Labs (CSE: CL) reported its second-quarter 2020 financials yesterday, posting revenue growth of 42%...

Friday, August 21, 2020, 04:03:00 PM